PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research0 citations

Efficacy Of Antibody Drug Conjugates In Advanced Metaplastic Breast Cancer

Abstract PS1-09-18: Efficacy of antibody drug conjugates in patients with advanced metaplastic breast cancer: a multi-institutional retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

SJSaya JacobSPSarah PremjiSFSamantha Fisch

Discussion

Loading...

Member takes

Overview

Multi-institutional cohort study reveals ADC effectiveness in metaplastic breast cancer, highlighting treatment challenges.

Key Points

  • The aim is to evaluate the efficacy of antibody-drug conjugates in patients with advanced metaplastic breast cancer and their response compared to conventional therapies.
  • Retrospective cohort study of patients diagnosed with metaplastic breast cancer
  • Patients received antibody-drug conjugate therapy across four NCI-designated cancer centers
  • Primary endpoints included objective response rate and real-world progression-free survival (rwPFS)
  • Identified 48 patients who received at least one antibody-drug conjugate
  • Objective response rate was 38%, with 4 complete responses observed
  • Median rwPFS for first-line ADC was 2.3 months, and 2.6 months for second-line ADC, showing similar outcomes compared to non-ADC therapy

Cite This Study

Jacob et al. (2026) studied this question.

synapsesocial.com/papers/6996a957ecb39a600b3f04c4https://doi.org/10.1158/1557-3265.sabcs25-ps1-09-18
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS4-08-29: Neoadjuvant antibody-drug conjugates for early-stage breast cancer: a systematic review and meta-analysis2026
  2. 2Abstract PS1-09-07: Central nervous system disease in patients with metaplastic breast cancer receiving antibody drug conjugates: a multi-institutional study2026
  3. 3Abstract PD3-09: Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network2026
  4. 4Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker Analysis2024 · 23 citations
  5. 5Abstract PS08-01: Antibody-Drug Conjugates (ADCs) in Breast Cancer: Real World Analysis of Outcomes2024 · 5 citations